Total Payments
$904,147
2024 Payments
$95,353
Companies
26
Transactions
599
Medicare Patients
22
Medicare Billing
$2,842
Payment Breakdown by Category
Consulting$506,410 (56.0%)
Research$147,810 (16.3%)
Travel$130,292 (14.4%)
Other$107,566 (11.9%)
Food & Beverage$10,043 (1.1%)
Education$2,027 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $506,410 | 157 | 56.0% |
| Unspecified | $147,810 | 125 | 16.3% |
| Travel and Lodging | $130,292 | 109 | 14.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $107,566 | 64 | 11.9% |
| Food and Beverage | $10,043 | 141 | 1.1% |
| Education | $2,027 | 3 | 0.2% |
Payments by Type
General
$756,337
474 transactions
Research
$147,810
125 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $191,230 | 147 | $0 (2024) |
| GENZYME CORPORATION | $163,162 | 98 | $0 (2024) |
| EMD Serono, Inc. | $93,272 | 50 | $0 (2023) |
| Novartis Pharma AG | $84,535 | 45 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $66,057 | 59 | $0 (2024) |
| Celgene Corporation | $51,144 | 33 | $0 (2021) |
| Genentech, Inc. | $49,820 | 45 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $48,637 | 12 | $0 (2023) |
| Hoffmann-La Roche Limited | $41,973 | 16 | $0 (2022) |
| Biogen, Inc. | $29,788 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $95,353 | 42 | GENZYME CORPORATION ($45,236) |
| 2023 | $70,725 | 48 | F. Hoffmann-La Roche AG ($28,098) |
| 2022 | $54,720 | 50 | NOVARTIS PHARMACEUTICALS CORPORATION ($12,762) |
| 2021 | $115,774 | 61 | F. Hoffmann-La Roche AG ($16,095) |
| 2020 | $89,116 | 58 | F. Hoffmann-La Roche AG ($32,440) |
| 2019 | $203,249 | 161 | SANOFI-AVENTIS U.S. LLC ($38,637) |
| 2018 | $160,606 | 105 | GENZYME CORPORATION ($41,512) |
| 2017 | $114,605 | 74 | Novartis Pharma AG ($38,799) |
All Payment Transactions
599 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $161.00 | Research |
| Study: Primary MS • Category: Immunology | ||||||
| 12/20/2024 | Shionogi Inc | S-740792 (Drug) | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| Category: Neurology | ||||||
| 12/05/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $6,850.00 | General |
| 11/11/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,237.79 | General |
| 10/08/2024 | Novartis Pharma AG | KESIMPTA (Drug) | Consulting Fee | Cash or cash equivalent | $7,550.00 | General |
| Category: NEUROSCIENCE | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $3,574.74 | Research |
| Study: Ocrelizumab vaccination study • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,983.60 | Research |
| Study: MNT OBOE • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,915.00 | Research |
| Study: A randomized, placebo and active-controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,498.46 | Research |
| Study: Fen Ph II RMS | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,478.00 | Research |
| Study: MNT OBOE • Category: Immunology | ||||||
| 09/20/2024 | GENZYME CORPORATION | — | — | In-kind items and services | $500.00 | Research |
| Study: A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 09/20/2024 | GENZYME CORPORATION | — | — | In-kind items and services | $250.00 | Research |
| Study: A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | ||||||
| 09/19/2024 | Novartis Pharma AG | KESIMPTA (Drug) | Education | In-kind items and services | $929.89 | General |
| Category: NEUROSCIENCE | ||||||
| 09/19/2024 | Novartis Pharma AG | KESIMPTA (Drug) | Travel and Lodging | In-kind items and services | $389.82 | General |
| Category: NEUROSCIENCE | ||||||
| 09/19/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $67.32 | General |
| 09/18/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $4,140.00 | General |
| 09/18/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $19.40 | General |
| 09/17/2024 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,035.00 | General |
| 09/17/2024 | Novartis Pharma AG | KESIMPTA (Drug) | Travel and Lodging | In-kind items and services | $246.23 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $23.92 | General |
| 09/16/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $2,070.00 | General |
| Category: Immunology | ||||||
| 08/02/2024 | Genentech, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $704.65 | General |
| Category: Immunology | ||||||
| 08/02/2024 | Genentech, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $675.35 | General |
| Category: Immunology | ||||||
| 07/16/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $561.45 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $12,762 | 11 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $10,097 | 18 |
| RPC01-201 - A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of | Celgene Corporation | $9,711 | 1 |
| A RANDOMIZED, PLACEBO AND ACTIVE-CONTROLLED DOSE FINDING STUDY TO EVALUATE THE EFFICACY, AS MEASURED BY BRAIN MRI LESIONS, AND SAFETY OF 2 DOSE REGIMENS OF OCRELIZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $9,596 | 1 |
| AN OPEN-LABEL, MULTICENTER, BIOMARKER STUDY TO EXPLORE THE MECHANISM OF ACTION OF OCRELIZUMAB AND B-CELL BIOLOGY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS OR PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $6,538 | 14 |
| RPC01-301 - A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclero | Celgene Corporation | $5,737 | 1 |
| A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis, A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis | F. Hoffmann-La Roche AG | $5,272 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $5,249 | 9 |
| A randomized, placebo and active-controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis | F. Hoffmann-La Roche AG | $4,737 | 2 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | Novartis Pharmaceuticals Corporation | $4,731 | 1 |
| A Phase IIIb, Multicenter, randomized, parallel-group, open-label study to evaluate the effects of ocrelizumab on immune responses in patients with Relapsing forms of multiple sclerosis | F. Hoffmann-La Roche AG | $4,617 | 1 |
| MNT OBOE | F. Hoffmann-La Roche AG | $4,470 | 3 |
| Fen Ph II RMS | F. Hoffmann-La Roche AG | $4,387 | 7 |
| Ocrelizumab vaccination study | F. Hoffmann-La Roche AG | $3,884 | 2 |
| A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients (RPC01-201) | Celgene Corporation | $3,818 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A PHASE III, MULTICENTRE, RANDOMIZED, PARALLEL-GROUP, DOUBLE BLINDED, PLACEBO CONTROLLED S | F. Hoffmann-La Roche AG | $3,713 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS, A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMPARISON TO INTERFERON BETA-1A REBIF IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $3,196 | 3 |
| A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis, A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a Rebif in Patients with Relapsing Multiple Sclerosis, A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled | F. Hoffmann-La Roche AG | $3,136 | 4 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients (RPC01-301) | Celgene Corporation | $2,866 | 1 |
| COMPARED WITH EVOBRUTINIB AND TOLEBRUTINIB, FENEBRUTINIB DISPLAYS HIGHEST IN VITRO POTENCY ON BOTH B CELLS AND MYELOID PROGENITOR LINEAGE CELLS | F. Hoffmann-La Roche AG | $2,866 | 2 |
| CBAF312AUS02 | Novartis Pharmaceuticals Corporation | $2,664 | 1 |
| OCRELIZUMAB REDUCES THALAMIC VOLUME LOSS IN PATIENTS WITH RMS AND PPMS | F. Hoffmann-La Roche AG | $2,411 | 1 |
| Publication support research related | Novartis Pharma AG | $2,403 | 2 |
| EXPLORING THE SAFETY AND TOLERABILITY OF CONVERSION TO DOSE TITRATED SIPONIMOD IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS A 6 MONTH OPEN LABEL MULTI CENTER PHASE III B STUDY EXPANDED | Novartis Pharmaceuticals Corporation | $2,083 | 1 |
| A 12 MONTH PROSPECTIVE MULTICENTER TWO COHORT NONRANDOMIZED OPEN LABEL STUDY IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RMS TO INVESTIGATE CHANGES IN IMMUNE PHENOTYPE BIOMARKERS AFTER TREATMENT WITH 05MG FINGOLIMOD FLUENT | Novartis Pharmaceuticals Corporation | $1,875 | 1 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO CONTROLLED VARIABLE TREATMENT DURATION STUDY EVALUATING THE EFFICACY AND SAFETY OF SIPONIMOD BAF312 IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS | Novartis Pharmaceuticals Corporation | $1,808 | 1 |
| A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MULTIPLE SCLEROSIS , A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $1,574 | 2 |
| EMPIRE Clinical | GENZYME CORPORATION | $1,567 | 1 |
| RPC01-201-PartA | Celgene Corporation | $1,463 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,437 | 4 |
| B-CELL SUBSET DEPLETION FOLLOWING OCRELIZUMAB TREATMENT IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $1,398 | 1 |
| Reduced Thalamic Atrophy in Patients Initiating Earlier Versus Delayed Ocrelizumab Therapy Results From The OLE of OPERA III and ORATORIO | F. Hoffmann-La Roche AG | $1,392 | 2 |
| Effect of Ocrelizumab on Thalamic Atrophy in Patients With Relapsing and Primary Progressive Multiple Sclerosis | F. Hoffmann-La Roche AG | $1,349 | 2 |
| RPC01-301 | Celgene Corporation | $1,251 | 1 |
| A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis | GENZYME CORPORATION | $1,250 | 1 |
| EFFECT OF OCRELIZUMAB ON CEREBELLAR ATROPHY IN RMS AND PPMS RESULTS FROM OPERA IOPERA II AND ORATORIO | F. Hoffmann-La Roche AG | $1,232 | 2 |
| Utility and implementation of a federated research infrastructure to assess lack of disease stability as a real-world surrogate of PIRA, by combining MS clinical trial and real-world cohort data (The INTONATE MS consortium) | F. Hoffmann-La Roche AG | $1,201 | 1 |
| Reduction of intrathecal immunoglobulin levels with ocrelizumab treatment in relapsing and primary progressive multiple sclerosis | F. Hoffmann-La Roche AG | $1,056 | 1 |
| RPC01-3001 - PhIII Efficacy And Safety of RPC1063 in Relapsing MS (RPC01-3001) | Celgene Corporation | $884.00 | 1 |
| AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $838.24 | 2 |
| RPC01-201 | Celgene Corporation | $834.00 | 1 |
| A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | GENZYME CORPORATION | $750.00 | 2 |
| Efficacy and Safety of Fenebrutinib, a Noncovalent, Reversible BTK inhibitor, in MS: Primary Results of a Phase 2 Trial | F. Hoffmann-La Roche AG | $694.42 | 1 |
| A Phase 2a/2b double-blind, randomized, placebo-controlled study assessing efficacy, safety, and dose-response of vatelizumab in patients with relapsing-remitting multiple sclerosis (RRMS) | GENZYME CORPORATION | $616.97 | 2 |
| Circulating B-cell and serum neurofilament light chain levels associated with progressive disease outcomes in Phase III trials of ocrelizumab in people with relapsing or progressive multiple sclerosis | F. Hoffmann-La Roche AG | $469.73 | 1 |
| RPC01-201-PartB and RADIANCE study | Celgene Corporation | $417.00 | 1 |
| Primary MS | F. Hoffmann-La Roche AG | $161.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 11 | 16 | $2,643 | $1,294 |
| 2022 | 1 | 11 | 11 | $3,905 | $1,548 |
Total Patients
22
Total Services
27
Medicare Billing
$2,842
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 16 | $2,643 | $1,294 | 49.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $3,905 | $1,548 | 39.6% |
About Amit Bar-Or
Amit Bar-Or is a Neurology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/06/2017. The National Provider Identifier (NPI) number assigned to this provider is 1528508843.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Amit Bar-Or has received a total of $904,147 in payments from pharmaceutical and medical device companies, with $95,353 received in 2024. These payments were reported across 599 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($506,410).
As a Medicare-enrolled provider, Bar-Or has provided services to 22 Medicare beneficiaries, totaling 27 services with total Medicare billing of $2,842. Data is available for 2 years (2022–2023), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Philadelphia, PA
- Active Since 03/06/2017
- Last Updated 03/06/2017
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1528508843
Products in Payments
- OCREVUS (Biological) $154,008
- LEMTRADA (Drug) $58,465
- Ocrevus (Biological) $54,864
- NO PRODUCT DISCUSSED (Drug) $36,573
- OMB157G (Drug) $34,004
- AUBAGIO (Drug) $26,251
- MAYZENT (Drug) $25,272
- Ozanimod (Drug) $18,448
- FTY720D_GILENYA_NEUROSCIENCE (Drug) $16,039
- KESIMPTA (Drug) $12,342
- ARZERRA (Drug) $12,175
- ZEPOSIA (Drug) $11,556
- OMB157G_ARZERRA_HEMATOLOGY (Drug) $8,571
- GILENYA (Drug) $7,742
- RPC-1063 (Drug) $6,684
- Evobrutinib $6,550
- COPAXONE (Drug) $6,080
- LEMTRADA (Biological) $5,530
- Mavenclad (Drug) $4,240
- UPLIZNA (Drug) $4,200
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Philadelphia
Dr. Thomas Leist, M.d, M.D
Neurology — Payments: $2.0M
Neurology $2.0M
Dr. Daniel Kremens, M.d., J.d, M.D., J.D
Neurology — Payments: $1.9M
Neurology $1.9M
Dr. Jill Giordano Farmer, Do, DO
Neurology — Payments: $1.1M
Neurology $1.1M
Dr. Stephen Silberstein, M.d, M.D
Neurology — Payments: $936,801
Neurology $936,801
Dr. Stephanie Nahas-Geiger, M.d, M.D
Neurology — Payments: $828,295
Neurology $828,295
Matthew Stern, Md, MD
Neurology — Payments: $517,599
Neurology $517,599